Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 4031-4041

  Wong, Tai W ^a   Lee, Francis Y ^a   Emanuel, Stuart ^a   Fairchild, Craig ^a   Fargnoli, Joseph ^a   Fink, Brian ^a   Gavai, Ashvinikumar ^a   Hammell, Amy ^a   Henley, Benjamin ^a   Hilt, Christine ^a   Hunt, John T ^a   Krishnan, Bala ^a,b   Kukral, Daniel ^a   Lewin, Anne ^a   Malone, Harold ^a   Norris, Derek ^a   Oppenheimer, Simone ^a   Vite, Gregory ^a   Yu, Chiang ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Pre clinical Imaging Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BMS 690514; BRIVANIB ALANINATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; PROTEIN HER4; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING ASSAY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; COLON CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; ENZYMATIC ASSAY; GENE MUTATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MITOSIS INHIBITION; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT DURATION; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959205978     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3417     Document Type: Article

References (47)

1. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-95. (Pubitemid 350002967)
2. Carter CA, Kelly RJ, Giaccone G. Small-molecule inhibitors of the human epidermal receptor family. Expert Opin Investig Drugs 2009;18:1829-42.
3. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.Clin Exp Immunol 2009;158:1-9.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuireWL, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987:235:177-82. (Pubitemid 17231334)
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for mestastatic breast cancer that overexpress HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
6. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43. (Pubitemid 46021510)
7. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009;41:1127-32.
8. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. (Pubitemid 46799492)
10. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, et al. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 2010;70:1989-99.
11. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010;316:1083-100.
12. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54. (Pubitemid 35204731)
13. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32s-40s.
14. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
15. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007;40:580-94. (Pubitemid 47063294)
16. Avizienyte E, Ward RA, Garner AP. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 2008;415:197-206.
17. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65. (Pubitemid 38697310)
18. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11.
19. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-32.
20. Hunt JT, Mitt T, Borzilleri R, Gullo-Brown J, Fargnoli J, Fink B, et al. Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template. J Med Chem 2004;47:4054-9.
21. Borzilleri RM, Cai ZW, Ellis C, Fargnoli J, Fura A, Gerhardt T, et al. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors. Bioorg Med Chem Lett 2005;15:1429-33.
22. Gavai AV, Fink BE, Fairfax DJ, Martin GS, Rossiter LM, Holst CL, et al. Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H- indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J Med Chem 2009;52:6527-30.
23. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000;55:15-35.
24. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. NatRev Clin Oncol 2009;6:569-79.
25. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18.
26. Dolf G, Meyn RE, Curley D, Prather N, Story MD, Boman BM, et al. Extrachromosomal amplification of the epidermal growth factor receptor gene in a human colon carcinoma cell line. Genes Chromosomes Cancer 1991;3:48-54.
27. Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 2005;116:36-44. (Pubitemid 40834296)
28. Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 1999;79:707-17. (Pubitemid 29082094)
29. Ziober BL, Willson JK, Hymphrey LE, Childress-Fields K, Brattain MG. Autocrine transforming growth factor-alpha is associated with progression of transformed properties in human colon cancer cells. J Biol Chem 1993;268:691-8. (Pubitemid 23021378)
30. Kellar KA, Ziober BL, Willson JK, Hymphrey LE, Childress-Fields K, Brattain MG. Autocrine transforming growth factor-alpha is associated with progression of transformed properties in human colon cancer cells. J. Biol. Chem. 1993;268:691-8.
31. Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006;12:6186-93. (Pubitemid 44703785)
32. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36. (Pubitemid 41094421)
33. Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 2010;9:369-78.
34. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010;36S3:S21-9.
35. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 1998;78:766-74. (Pubitemid 28530401)
36. Shadeo A, Lam WL. Comprehensive copy number profiles of breast cancer cell model genomes. Breast Cancer Res 2006;8:1-14.
37. Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007;46:543-58. (Pubitemid 46649569)
38. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009;4:e4576.
39. Cheng QC, Tikhomirov O, Zhou W, Carpenter G. Ectodomain cleavage of erbB-4. J Biol Chem 2003;278:38421-7.
40. Maatta JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, et al. Proteolytic cleavage and phosphorylation of a tumor-associated erbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 2006;17:67-79. (Pubitemid 43049462)
41. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68:5878-87.
42. Arteaga CL, Ramsey TT, Shawver LK, Guyer CA. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinzolines with the ATP binding site. J Biol Chem 1997;272:23247-54. (Pubitemid 27392460)
43. Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cell. Clin Cancer Res 2003;9:1274-83. (Pubitemid 36418377)
44. Marathe P, Tang Y, Sleczka B, Rodrigues D, Gavai A, Wong T, et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor ofEGFRand VEGFR2. J Pharm Sci 2010;99:3579-93.
45. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-6.
46. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, et al. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.Oncogene 2010;29:325-34.
47. Loriot Y, Mordant P, Dorvault N, De la motte Rouge T, Bourhis J, Soria JC, et al. BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. Br J Cancer 2010;103:347-353.